Peptide Product Composition: Glucagon vs Glucose – Key Differences Explained
Abstract: Glucagon and glucose, both critical in glycemic management, represent distinct peptide product compositions. Glucagon, a 29-amino-acid polypeptide, acts via G-protein-coupled receptors to counter hypoglycemia, while glucose is a monosaccharide. Market trends show glucagon’s CAGR at 8.5% (2023-2030), driven by rescue therapies and dual-hormone pumps. Key differences include mechanism (receptor-mediated vs. direct absorption), stability (glucagon requires cold-chain logistics; glucose is ambient-stable), and regulatory status (glucagon requires FDA/EMA peptide-specific certifications). Brand comparisons (e.g., Baqsimi vs. Gvoke) highlight bioavailability and device ergonomics. Industry data indicate glucagon’s superior efficacy in severe hypoglycemia (≥95% recovery within 15 min) versus glucose’s 70% oral efficacy. Sourcing demands GMP-certified peptide factories with HPLC purity >98%.